2020 American Transplant Congress
Treatment Strategies to Suppress Donor Specific Antibodies: Highlights from a Decade of Research Experience in a Mouse Model of Allo-Sensitization
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Difficulty in desensitization in highly sensitized patients remain problematic in organ transplantation. For over 12 years, our laboratory has been carrying out an HLA…2020 American Transplant Congress
B Cell Derived IL-1β and IL-6 Drive Homeostatic T Cell Recovery Following Lymphoablation
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: T cell reconstitution after lymphoablation in allograft recipients may lead to acute rejection and poor graft outcome. Using a mouse model of heart transplantation…2020 American Transplant Congress
Next Generation Sequencing B Cell Receptor Reveals B Cell Clones Encoding HLA Antibody in Transplant Recipients
HLA and Immunogenetcis Laboratory /CTC, Cedars Sinai Medical Center, Los Angeles, CA
*Purpose: The development of HLA donor specific antibodies (DSA) increases the risk of antibody mediated rejection and is an independent predictor of poor patient survival.…2020 American Transplant Congress
Effect of Rituximab Dose as Induction Therapy in ABO Incompatible Living Kidney Transplantation A Systemic Review and Network Meta Analysis
1Inha University, Incheon, Korea, Republic of, 2Keimyung University, Daegu, Korea, Republic of
*Purpose: ABO-incompatible living kidney transplantation (ABOILKT) has steadily become more widespread. However, the optimal immunosuppressive regimen for ABOILKT remains uncertain. We aimed to determine the…2020 American Transplant Congress
Recipient LAG3 Deficiency Results in Antibody-Mediated Rejection of Mouse Renal Allografts
Inflammation and Immunity, Cleveland Clinic, Cleveland, OH
*Purpose: Lymphocyte activation gene-3 (LAG3) is a coinhibitory receptor on the surface of T and B lymphocytes, NK cells and plasmacytoid dendritic cells. Its functions…2020 American Transplant Congress
BAFF Inhibition to Prevent Antibody Rebound Following Proteasome Inhibitor-Based Desensitization: A Randomized, Controlled Trial
*Purpose: Proteasome inhibitor (PI) therapy reduces bone marrow plasma cells and HLA antibodies (Abs) in renal transplant candidates. However, rebound is common in many patients…2020 American Transplant Congress
Immune Cell Subset Profiles in HLA-Sensitized Kidney Transplant Patients (HS KTx Pts) Desensitized with Clazakizumab (CLZ, Humanized Anti-IL-6 Monoclonal Antibody) Followed by Transplantation (Tx)
*Purpose: IL-6, B cell growth factor, increases follicular T helper cell (Tfh) activity, promoting plasmablast (PB) and plasma cell (PC) differentiation, and antibody production. A…2020 American Transplant Congress
Investigation of Il35 Expressing Regulatory B Cells in Tolerance of Kidney Transplantation
Surgery, University of Wisconsin, Madison, WI
*Purpose: The development and maintenance of peripheral tolerance is required for long term success of solid organ transplantation without immuno-suppressive drugs. Using a novel, post-transplant,…2020 American Transplant Congress
Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up
*Purpose: IL-6 mediates inflammation and activation of T-cells, B-cells & plasma cells. Thus, IL-6 may represent an important target for desensitization (DES). Here we report…2020 American Transplant Congress
Bone Marrow Plasma Cell Heterogeneity Drives Resistance of Proteasome Inhibitor Therapy
*Purpose: Patients sensitized to HLA antigens by prior transplantation, pregnancy or blood transfusion may have markedly prolonged waiting times for transplant. Moreover, once transplanted, the…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 35
- Next Page »